bioAffinity Technologies, Inc.
BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.āāā ā
Healthcare
Diagnostics & Research
3 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.24
Price+2.06%
$0.02
1Y
Price
Market Cap
$5.578m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-340.9%
EBITDA Margin-349.3%
Net Profit Margin-171.3%
Free Cash Flow MarginRevenue
$6.777m
-27.6%
1y CAGR+17630.7%
3y CAGR+13223.0%
5y CAGREarnings
-$14.739m
-63.0%
1y CAGR-24.8%
3y CAGR-25.8%
5y CAGREPS
-$20.61
+8.4%
1y CAGR+25.2%
3y CAGR-8.7%
5y CAGRBook Value
$8.902m
$11.546m
Assets$2.644m
Liabilities$680.950k
DebtDebt to Assets
5.9%
-
Debt to EBITDAFree Cash Flow
-$8.507m
-15.8%
1y CAGR-26.1%
3y CAGR-46.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company